Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

The acquisition of HS-20094 enhances Regeneron’s portfolio ... studies with Regeneron’s proprietary drugs to address muscle loss and other obesity comorbidities, such as cardiovascular ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Is Regeneron a good stock to buy now in light of a potential 23andMe acquisition ... turn all that genetic data into new blockbuster drugs. A few years before 23andMe became a publicly traded ...

Regeneron Pharmaceuticals ... genetic data as part of its drug research for more than a decade, is augmenting its capabilities in a big way with the $256 million acquisition of assets from ...